Abstract Number: 349 • 2018 ACR/ARHP Annual Meeting
Improving the Performance of the Spanish Version of QOL-RA
Background/Purpose: We have recently validated the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA). Redundancy between questions Nº 3 and Nº 6 was observed, and it was…Abstract Number: 350 • 2018 ACR/ARHP Annual Meeting
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
Background/Purpose: Checkpoint immunotherapy has become the standard of care in treating advanced melanoma. These medications have been associated with immune-related adverse events (irAEs). Accurate methods…Abstract Number: 351 • 2018 ACR/ARHP Annual Meeting
Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
Background/Purpose: To evaluate the prevalence and type of rheumatic immune-related adverse events (IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods: This is…Abstract Number: 352 • 2018 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
Background/Purpose: Rheumatic immune related adverse events (irAEs) from checkpoint inhibitor (ICI) therapy remain poorly understood. In our early experience with rheumatic irAEs we encountered patients…Abstract Number: 353 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
Background/Purpose: Immune checkpoint blockade therapy (ICTB) has shown remarkable benefit in different cancer types. Blockade of intrinsic down-regulators of immunity increases the activity of the…Abstract Number: 354 • 2018 ACR/ARHP Annual Meeting
Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Background/Purpose: Immune checkpoint inhibitors (ICIs) have led to improved outcomes in multiple cancers, but they are associated with immune-related adverse events (irAEs), including inflammatory arthritis.…Abstract Number: 355 • 2018 ACR/ARHP Annual Meeting
Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Background/Purpose: Immune checkpoint inhibitors (ICI), an important type of cancer therapy, can cause adverse events through immune activation. Inflammatory arthritis (IA) due to ICI treatment…Abstract Number: 356 • 2018 ACR/ARHP Annual Meeting
Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting CTLA-4, such as ipilimumab (anti-CTLA4), or PD-1/PD-L1, such as nivolumab and pembrolizumab are increasingly utilized in a wide variety…Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…Abstract Number: 358 • 2018 ACR/ARHP Annual Meeting
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Background/Purpose: Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related…Abstract Number: 359 • 2018 ACR/ARHP Annual Meeting
Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis
Background/Purpose: Checkpoint inhibitors (ICIs) are revolutionizing cancer treatment; however, ICI therapy is associated with immune-related adverse events (irAEs). irAEs can be life-threatening and/or severely impair…Abstract Number: 360 • 2018 ACR/ARHP Annual Meeting
Sarcoidosis Induced By Immune Check Point Inhibitors
Background/Purpose: Immune check point inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have demonstrated improved survival for multiple cancers…Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…Abstract Number: 362 • 2018 ACR/ARHP Annual Meeting
Immune Check Point Inhibitors, Auto-Antibodies, and Immune Adverse Reactions
Background/Purpose: Immune checkpoint inhibitors (ICI) targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) and its ligand PD-L1 have had substantial…Abstract Number: 363 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
Background/Purpose: Over the years there has been a huge effort to change the traditional way to treat cancer, that was previously based on chemotherapy and/or…
ACR Meeting Abstracts